Show simple item record

dc.rights.licenseopenen_US
dc.contributor.authorDELJEHIER, T.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPARIENTE, Antoine
IDREF: 13395711X
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMIREMONT-SALAME, Marie Ghada
ORCID: 0000-0002-6468-8903
IDREF: 153165766
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorHARAMBURU, Francoise
IDREF: 59522674
dc.contributor.authorNGUYEN, L.
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorRUBIN, Sebastien
dc.contributor.authorRIGOTHIER, C.
dc.contributor.authorTHEOPHILE, H.
dc.date.accessioned2020-11-03T11:09:40Z
dc.date.available2020-11-03T11:09:40Z
dc.date.issued2018-05
dc.identifier.issn1365-2125 (Electronic) 0306-5251 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/11593
dc.description.abstractEnFollowing a severe case of rhabdomyolysis in our University Hospital after a co-administration of atorvastatin and fusidic acid, we describe this interaction as this combination is not clearly contraindicated in some countries, particularly for long-term treatment by fusidic acid. All cases of rhabdomyolysis during a co-administration of a statin and fusidic acid were identified in the literature and in the World and Health Organization database, VigiBase(R). In the literature, 29 cases of rhabdomyolysis were identified; mean age was 66 years, median duration of co-administration before rhabdomyolysis occurrence was 21 days, 28% of cases were fatal. In VigiBase(R), 182 cases were retrieved; mean age was 68 years, median duration of co-administration before rhabdomyolysis was 31 days and 24% of cases were fatal. Owing to the high fatality associated with this co-administration and the long duration of treatment before rhabdomyolysis occurrence, fusidic acid should be used if there is no appropriate alternative, as long as statin therapy is interrupted for the duration of fusidic acid therapy, and perhaps a week longer. Rarely will interruption of this sort have adverse consequences for the patient.
dc.language.isoENen_US
dc.subject.enPharmacoEpi-Drugs
dc.title.enRhabdomyolysis after co-administration of a statin and fusidic acid: an analysis of the literature and of the WHO database of adverse drug reactions
dc.title.alternativeBr J Clin Pharmacolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/bcp.13515en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed29337401en_US
bordeaux.journalBritish Journal of Clinical Pharmacologyen_US
bordeaux.page1057-1063en_US
bordeaux.volume5en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERM
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03193776
hal.version1
hal.date.transferred2021-04-09T07:32:39Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=British%20Journal%20of%20Clinical%20Pharmacology&rft.date=2018-05&rft.volume=5&rft.spage=1057-1063&rft.epage=1057-1063&rft.eissn=1365-2125%20(Electronic)%200306-5251%20(Linking)&rft.issn=1365-2125%20(Electronic)%200306-5251%20(Linking)&rft.au=DELJEHIER,%20T.&PARIENTE,%20Antoine&MIREMONT-SALAME,%20Marie%20Ghada&HARAMBURU,%20Francoise&NGUYEN,%20L.&rft.genre=article


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record